“PRKAG2.2 Variant Necessary for Differentiation and Metabolic Rewiring of FoxA1(+) Tregs, Implicating Potential Therapeutic Targets for Autoimmune Diseases”

https://pubmed.ncbi.nlm.nih.gov/38117896

The study finds that the PRKAG2.2 variant is essential for the differentiation and metabolic rewiring of a distinct subset of regulatory T cells (FoxA1(+) Tregs), which are effective in exerting anti-inflammatory properties, suggesting potential therapeutic targets for autoimmune diseases.